Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company that develops and commercializes medicines focused on oncology, autoimmune, and infectious disease. The company generates revenue primarily through product sales of its approved therapies, supplemented by collaboration and licensing arrangements with global partners. Zai Lab is headquartered at 314 Main Street, Cambridge, MA, with ordinary shares listed on the Stock Exchange of Hong Kong Limited. The 10-K filed 2026-02-26 (accession 000170429226000015) covers the fiscal year ended in that period. The company operates at the intersection of global biotech partnerships and China-focused commercialization, in-licensing assets from multinational pharmaceutical companies and advancing them through regulatory approval and commercial launch in its core markets.

Revenue model

Product sales from commercialized therapies and collaboration or licensing income from partnership agreements with global biopharmaceutical companies.

Products and services

Approved and investigational therapies in oncology, autoimmune disease, and infectious disease, developed through in-licensing and internal R&D.

Customers and end markets

Patients and healthcare providers in oncology, autoimmune, and infectious disease end markets, primarily in China and select global markets.

Value-chain role

Drug developer and commercial-stage biopharmaceutical company; in-licenses assets from global partners and handles regional regulatory approval and commercialization.

Geographic exposure

Headquarters in Cambridge, MA, USA; ordinary shares listed on the Stock Exchange of Hong Kong Limited; primary commercial operations in China.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations